NovoCure Ltd 8-K

What Happened

• NovoCure Ltd disclosed on Form 8-K (filed Feb 5, 2026) that its U.S. subsidiary, Novocure Inc., received a letter from the Centers for Medicare & Medicaid Services (CMS) dated Jan 29, 2026 notifying that the Company’s billing privileges were revoked retroactive to Dec 17, 2025.
• The revocation was attributed to an administrative process issue related to the Company’s triannual re‑validation (not a substantive failure to qualify). Novocure has submitted a Corrective Action Plan to CMS and expects reinstatement but cannot predict timing or final outcome.
• While the reinstatement process is pending, Novocure is continuing to provide services and accept new patients, but it is not permitted to bill Medicare, Medicare Advantage or other CMS-related payors for services rendered since the revocation date.

Key Details

• Revocation notice dated: January 29, 2026; effective retroactively from: December 17, 2025.
• Estimated revenue impact: approximately $13 million per month in lost recognized revenue from CMS payors until billing privileges are reinstated.
• Company action: Corrective Action Plan filed with CMS; will attempt retroactive billing after reinstatement but cannot predict whether or how much will be recoverable.
• Disclosure filed under Item 7.01 (Regulation FD Disclosure) of Form 8‑K; forward‑looking statement caution included.

Why It Matters

• For investors, the immediate practical effect is suspended Medicare/CMS billing for services provided since Dec 17, 2025, which the company estimates could reduce recognized revenue by about $13M per month until resolved.
• The situation creates uncertainty around near-term revenue, collections from third‑party payors, and timing of cash receipts; the company’s ability to recover retroactive amounts is not yet known.
• Novocure continues patient care operations, but investors should watch for updates on CMS reinstatement, any retroactive reimbursement outcomes, and related impacts on quarterly financial results.